Hiatt William R
Section of Vascular Medicine, Divisions of Geriatrics and Cardiology, University of Colorado, Health Sciences Center, Colorado Prevention Center, 789 Sherman Street, Suite 200, Denver, CO 80203, USA.
Atheroscler Suppl. 2005 Dec 15;6(4):21-31. doi: 10.1016/j.atherosclerosissup.2005.09.004. Epub 2005 Nov 4.
The management of peripheral arterial disease (PAD) patients with intermittent claudication (IC) requires both aggressive risk management and targeted symptomatic therapies. The phosphodiesterase inhibitor cilostazol is the only US Food and Drug Administration (FDA) approved medication to demonstrate consistent benefits on both objective measures of exercise capacity and subjective measures of everyday functioning and quality of life. Pentoxifylline is also approved by the FDA for the treatment of claudication, but with less clinical benefit than cilostazol. This report will provide an overview of cilostazol's role in the treatment of patients with IC. Data will be presented regarding the safety and efficacy demonstrated by cilostazol in clinical trials, as well as the effects of risk-factor control, exercise therapy, revascularization, and experimental drugs on the treatment of claudication in the PAD population. Based on the available evidence, a comprehensive approach to claudication management is recommended.
间歇性跛行（IC）外周动脉疾病（PAD）患者的管理需要积极的风险管理和针对性的症状治疗。磷酸二酯酶抑制剂西洛他唑是唯一获得美国食品药品监督管理局（FDA）批准的药物，已证实其在运动能力客观指标以及日常功能和生活质量主观指标方面均具有持续益处。己酮可可碱也获FDA批准用于治疗跛行，但临床获益程度低于西洛他唑。本报告将概述西洛他唑在IC患者治疗中的作用。将展示西洛他唑在临床试验中所证实的安全性和有效性数据，以及危险因素控制、运动疗法、血运重建和实验性药物对PAD人群跛行治疗的影响。基于现有证据，推荐采用综合方法管理跛行。
